Cardiovascular Therapeutics最新文献

{"title":"Joint Association of Cholesterol, High-Density Lipoprotein and Glucose Index, and Circadian Syndrome With Incidence of Cardiovascular Disease: Results From National Longitudinal Prospective Studies","authors":"Shenghao Jiang","doi":"10.1155/cdr/1001613","DOIUrl":"10.1155/cdr/1001613","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The cholesterol, high-density lipoprotein, and glucose (CHG) index and circadian syndrome (CircS) are potential contributors for cardiovascular disease (CVD). This study evaluated their independent, combined associations, and interactions with CVD risk.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study included participants aged ≥ 45 years without baseline CVD. Participants were classified according to the median or quartile levels of the CHG index and the binary status of CircS. Univariate and multivariate Cox regression models, along with Fine–Gray competing risk models assessed individual and joint effects. Both additive and multiplicative interactions were evaluated. Restricted cubic spline (RCS) analyses were conducted to visualize the dose–response relationship between the CHG index and CVD risk. Receiver operating characteristic (ROC) curve analyses assessed the predictive performance with the SCORE2 Asia-Pacific model for CVD at multiple time points.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 6739 eligible participants, 1420 (21.1%) participants developed CVD during follow-up. Both higher CHG index and CircS were independently associated with increased CVD risk. Compared with low CHG index and no CircS, participants with high CHG index and CircS had higher CVD risk (hazard ratio (HR)): 1.67, 95% confidence interval (CI): 1.46–1.90). No significant additive or multiplicative interactions were observed, but the significant ones were identified in external validation ELSA cohort. Integrating CHG index and CircS modestly improved SCORE2 Asia-Pacific model predictions, especially for 5-, 7-, and 9-year long-term CVD risk.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Elevated CHG index and CircS independently associated with a higher risk of CVD. Significant interactions were identified, incorporating them into the SCORE2 Asia-Pacific model modestly enhances long-term CVD risk prediction. These readily measurable markers may therefore be applied to earlier identify high-risk individuals, enabling more targeted CVD prevention strategies and optimize risk management in clinical practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/1001613","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148403721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Effectiveness and Safety of Interventions for Atrial Fibrillation in Heart Failure: A Network Meta-Analysis of Randomized Trials","authors":"Changjiang Deng,&nbsp;Yixin Xu,&nbsp;Adilai Adilijiang,&nbsp;Zhilong Wang,&nbsp;Ying Pan,&nbsp;Chao Fan,&nbsp;Baichuan Liu,&nbsp;Haoxu Lv,&nbsp;Junrui Hou,&nbsp;Tingting Wu","doi":"10.1155/cdr/6035178","DOIUrl":"10.1155/cdr/6035178","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with HF and AF face high risks of death and HF decompensation, yet the comparative effectiveness of commonly used AF management strategies remains uncertain. This study is aimed at comparing the efficacy and safety of different interventional and medical approaches using NMA of RCTs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PubMed, Embase, CENTRAL, Web of Science, and Google Scholar were searched from inception to November 30, 2025, without language restrictions. Parallel-group RCTs enrolling adults with clinically diagnosed HF and documented AF were eligible if they compared at least two AF management strategies, including CA, AVNA with CRT or RV pacing, MRC, drug-based rhythm control (rhythm drug), or CON. Primary outcomes were all-cause mortality and HF hospitalization; secondary outcomes were worsening HF, CV mortality, QoL, and LVEF. Random-effects NMA was performed in Stata 17.0, reporting ORs and SMDs with 95% CIs; treatments were ranked using SUCRA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-three RCTs (5159 patients) were included. For all-cause mortality (21 trials; 5095 patients), AVNA_CRT (OR, 0.30; 95% CI, 0.12–0.78) and CA (OR, 0.53; 95% CI, 0.35–0.82) were associated with lower mortality than CON; AVNA_CRT also outperformed MRC (OR, 0.35; 95% CI, 0.15–0.79) and AVNA_RV (OR, 0.49; 95% CI, 0.25–0.96). For HF hospitalization (9 trials; 3491 patients), AVNA_CRT reduced risk compared with AVNA_RV (OR, 0.20; 95% CI, 0.04–0.94). For worsening HF (7 trials; 2542 patients), AVNA_CRT was superior to AVNA_RV (OR, 0.41; 95% CI, 0.20–0.84). CA improved QoL versus AVNA_CRT (SMD, −0.94; 95% CI, −1.83 to −0.05) and MRC (SMD, −0.73; 95% CI, −1.22 to −0.24), and improved LVEF versus MRC (SMD, 1.49; 95% CI, 0.57–2.41). No between-strategy differences were clearly demonstrated for CV mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In RCT evidence for HF with AF, AVNA_CRT and CA were associated with more favorable prognostic outcomes, and CA provided more consistent improvements in QoL and LVEF. When AVNA is selected, CRT should be preferred over RV pacing. Strategy choice should be individualized to clinical goals, patient phenotype, and procedural feasibility.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/6035178","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Network Pharmacology and Experimental Validation Approach to Systematically Elucidate the Cardioprotective Mechanisms of Shengmai Injection","authors":"Nan Hu,&nbsp;Hongnv Zhang,&nbsp;Zhenghao Wang,&nbsp;Shaodong Zhai,&nbsp;Ruiping Zhang","doi":"10.1155/cdr/6915907","DOIUrl":"10.1155/cdr/6915907","url":null,"abstract":"<p>Core to advancing the study of traditional Chinese medicine (TCM) mechanisms is the integrated “computational prediction–experimental verification” strategy, which enables the precise identification of therapeutic targets through multilevel technological integration. Within this framework, this study systematically investigates the therapeutic mechanisms of Shengmai injection (SMI) against heart failure following myocardial infarction (MI). Initially, using network pharmacology approaches, we systematically screened TCMSP, BATMAN, and disease databases to identify 237 common targets of SMI and chronic heart failure. Through Cytoscape-based network topology analysis, we pinpointed 52 core targets, with KEGG pathway enrichment analysis revealing the PI3K-AKT signaling pathway as the crucial pathway. Subsequently, molecular docking technology demonstrated strong binding affinity (calculated affinity: −6.171 kcal/mol) between vitamin E (an active constituent by network pharmacology analysis) and the core target AKT1. At the experimental validation level, we established a mouse MI model by ligating the left anterior descending coronary artery, with continuous administration of SMI for 4 weeks. Experimental results showed that SMI significantly improved cardiac function of chronic heart failure, reduced myocardial fibrosis, inhibited cardiomyocyte apoptosis, and promoted macrophage polarization toward the reparative M2 phenotype. In the H9c2 cell model, SMI effectively improves mitochondrial function of cardiac cells induced by H₂O₂ and inhibits reactive oxygen species accumulation and mitochondrial membrane potential collapse. Mechanistic studies revealed that SMI regulates mitochondrial dysfunction by activating the AKT/Bcl-2 signaling axis, upregulating Bcl-2 expression, and inhibiting Bax. Through systematic methodological integration, this study not only elucidates the mechanism by which SMI inhibits mitochondrial dysfunction and macrophage polarization and attenuates ventricular remodeling through the AKT/Bcl-2 pathway but also provides a referential multidisciplinary research paradigm for investigating the mechanisms of TCM formulations.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/6915907","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148344102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prasugrel: Reassessing Its Role in Contemporary Antiplatelet Therapy","authors":"Yusof Kamisah,&nbsp;Hamat Hamdi Che Hassan","doi":"10.1155/cdr/5538781","DOIUrl":"https://doi.org/10.1155/cdr/5538781","url":null,"abstract":"<p>Managing acute coronary syndrome (ACS) and atherosclerotic cardiovascular disease remains clinically challenging, requiring a careful balance between ischemic protection and bleeding risk. Antiplatelet therapy is central to the management, with aspirin serving as the cornerstone; however, selection of the second antiplatelet agent in dual antiplatelet therapy (DAPT) remains complex. Clopidogrel, a purinergic receptor subtype Y, G protein–coupled, 12 (P2Y₁₂) inhibitor, is widely used but is limited by substantial interindividual variability in antiplatelet response, particularly in populations with a high prevalence of CYP2C19 loss-of-function polymorphisms. These limitations prompted the development of more potent P2Y₁₂ inhibitors, including prasugrel and ticagrelor, which provide faster and more consistent platelet inhibition. However, clinical experience—especially in Asian populations—has highlighted that a “one-size-fits-all” dosing strategy may not be appropriate, as heightened bleeding risk can offset ischemic benefit. This review reexamines the contemporary role of prasugrel, focusing on evidence supporting dose optimization, careful patient selection, and population-specific considerations. Current evidence suggests that prasugrel remains a valuable antiplatelet option when tailored to individual ischemic and bleeding risks, particularly in patients undergoing complex percutaneous coronary intervention and selected Asian populations requiring individualized antiplatelet strategies.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/5538781","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148324724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study”","authors":"","doi":"10.1155/cdr/9891810","DOIUrl":"10.1155/cdr/9891810","url":null,"abstract":"<p>B. Wang, Y. Song, Y. Fan, and Z. Zhao, “Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study,” <i>Cardiovascular Therapeutics</i>, no. 2026 (2026). https://doi.org/10.1155/cdr/1649836.</p><p>In the article titled “Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study,” there were multiple errors. These errors are shown and corrected below:</p><p><b>Error in Section 2.1:</b></p><p>The number of intensive care databases used in the study described was incorrect. The study only utilized the MIMIC-IV dataset, and the relevant information in this section should be corrected as follows:</p><p>[“This retrospective cohort study was conducted using data sourced from two accessible intensive care databases: the Medical Information Mart for Intensive Care IV (MIMIC-IV) (v3.1). MIMIC-IV contains comprehensive clinical data for over 450,000 hospitalizations at the Beth Israel Deaconess Medical Center from 2008 to 2019. The author, Bingfu Wang, was authorized to access both databases via the PhysioNet platform upon completion of the Collaborative Institutional Training Initiative (CITI) Program′s human subjects research course (Certificate No. 13971877).”]</p><p>should read:</p><p>[“This retrospective cohort study was conducted using data sourced from the Medical Information Mart for Intensive Care IV (MIMIC-IV) (v3.1) database. MIMIC-IV contains comprehensive clinical data for over 450,000 hospitalizations at the Beth Israel Deaconess Medical Center from 2008 to 2019. The author, Bingfu Wang, was authorized to access the database via the PhysioNet platform upon completion of the Collaborative Institutional Training Initiative (CITI) Program′s human subjects research course (Certificate No. 13971877).”]</p><p><b>Error in author affiliations:</b></p><p>The affiliations of the listed authors Yulong Song, Yujian Fan, and Zhiqiang Zhao were incorrect. The corrected affiliations appear below:</p><p>Bingfu Wang^1,2,3, Yulong Song^2,3, Yujian Fan^2,3, and Zhiqiang Zhao^2,3</p><p>¹Department of Cardiovascular Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China</p><p>²First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China</p><p>³National Clinical Research Center for Chinese Medicine, Tianjin, China</p><p>We apologize for these errors.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/9891810","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Ejection Fraction as a Modifier of Beta-Blocker Therapeutic Effects in Post-Acute Coronary Syndrome Patients With Non-Reduced Ejection Fraction: A Systematic Review and Meta-Analysis","authors":"Seyed Alireza Mirhosseini,&nbsp;Seyed Amir Sadrzadeh,&nbsp;Davood Semirani-Nezhad,&nbsp;Erta Rajabi,&nbsp;Hanieh Mohammadi,&nbsp;Alireza Shaabanpoor Haghighi,&nbsp;Mohammad Amin Jamali,&nbsp;Reza Moshfeghinia,&nbsp;Maryam Ranjbar,&nbsp;Pouria Azami,&nbsp;Rahul Gupta,&nbsp;Wilbert S. Aronow,&nbsp;Armin Attar","doi":"10.1155/cdr/2988999","DOIUrl":"10.1155/cdr/2988999","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Beta-blockers are regarded as one of the primary treatment options for acute coronary syndrome (ACS) patients with reduced left ventricular ejection fraction (LVEF). However, there is ongoing debate about their therapeutic efficacy in patients with non-reduced LVEF (≥ 40%).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To determine the impact of long-term beta-blocker administration on major adverse cardiovascular events (MACE) in ACS patients with LVEF ≥ 40&lt;i&gt;%&lt;/i&gt;.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A thorough literature search across four databases was conducted to identify eligible studies comparing beta-blocker therapy with placebo or no medication in addition to standard ACS pharmacotherapy. The outcomes of interest included all-cause mortality and MACE (comprising cardiovascular mortality, recurrent myocardial infarction [Re-MI], stroke, rehospitalization for heart failure, and revascularization). Based on LVEF values, patients were divided into three groups: (1) LVEF &gt; 40&lt;i&gt;%&lt;/i&gt;, (2) 40&lt;i&gt;%&lt;/i&gt; &lt; LVEF &lt; 50&lt;i&gt;%&lt;/i&gt;, and (3) LVEF ≥ 50&lt;i&gt;%&lt;/i&gt;, and the random-effects meta-analysis estimated the risk ratios (RRs), hazard ratios (HRs), and 95% confidence intervals (CIs).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Five randomized controlled trials (RCTs) and 19 observational studies met the inclusion criteria. Within the RCTs, beta-blocker use was associated with a non-significant 6% reduction in MACE (RR = 0.94, 95&lt;i&gt;%&lt;/i&gt;CI = 0.87–1.02, &lt;i&gt;I&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 19.1&lt;i&gt;%&lt;/i&gt;). The pooled analyses of observational studies showed no significant overall impact of beta-blocker use on endpoint outcomes. Subgroup analyses revealed a reduction in MACE (HR = 0.75, 95&lt;i&gt;%&lt;/i&gt;CI = 0.59–0.95, &lt;i&gt;I&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 0&lt;i&gt;%&lt;/i&gt;) and Re-MI (HR = 0.45, 95&lt;i&gt;%&lt;/i&gt;CI = 0.23–0.89) in patients with LVEF 40%–49%; however, these findings were derived primarily from observational data. Patients with LVEF ≥ 50&lt;i&gt;%&lt;/i&gt; did not appear to benefit from long-term beta-blocker use.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Long-term beta-blocker use did not show a significant benefit in patients with preserved ejection fraction (LVEF ≥ 50&lt;i&gt;%&lt;/i&gt;). Observational data suggested a possible reduction in MACE and Re-MI in the LVEF 40%–49% subgroup; however, this finding requires confirmation in dedicated RCTs. Future larger RCTs are needed to clarify the role of beta-blockers in this borderline population.&lt;/p&gt;\u0000 ","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/2988999","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prognostic Value of Different Patterns of Neoatherosclerosis and Treatment Modality in Patients With Coronary In-Stent Restenosis","authors":"Youcheng Shen,&nbsp;Ning Gu,&nbsp;Zhijiang Liu,&nbsp;Wei Zhang,&nbsp;Changyin Shen,&nbsp;Xi Wang,&nbsp;Chancui Deng,&nbsp;Qianhang Xia,&nbsp;Yongchao Zhao,&nbsp;Bei Shi","doi":"10.1155/cdr/2279738","DOIUrl":"10.1155/cdr/2279738","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Neoatherosclerosis (NA) and treatment modality may influence outcomes in patients with in-stent restenosis (ISR). This study evaluated the prognostic impact of different NA patterns and percutaneous coronary intervention (PCI) strategies guided by optical coherence tomography (OCT).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed 288 ISR lesions with OCT-defined NA treated between January 2015 and December 2023. Lesions were classified as lipidic, calcified, or mixed NA. The primary endpoint was 1-year target lesion failure (TLF), defined as a composite of cardiac death, nonfatal myocardial infarction, and clinically driven target lesion revascularization (CD-TLR). Cox regression, interaction analysis, and propensity score matching (PSM) were performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>No significant differences in TLF (<i>p</i> = 0.420) or CD-TLR (<i>p</i> = 0.650) were observed among NA patterns. After adjustment for clinical and procedural covariates, DES reimplantation was associated with a lower risk of TLF (hazard ratio [HR] 0.390, 95% confidence interval [CI] 0.157–0.974; <i>p</i> = 0.044) and CD-TLR (HR: 0.341, 95% CI: 0.114–0.925; <i>p</i> = 0.039) compared with DCB angioplasty. In patients with lipidic NA, a similar trend was observed (TLF: HR: 0.287; 95% CI: 0.097–0.849; <i>p</i> = 0.024; CD-TLR: HR: 0.171; 95% CI: 0.039–0.750; <i>p</i> = 0.019). However, no significant interaction was observed between the NA pattern and treatment modality (<i>p</i> for interaction = 0.543).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>No significant differences in clinical outcomes were observed across NA patterns. Although DES showed numerically favorable outcomes in lipidic NA, no significant interaction between NA pattern and treatment modality was detected. And these findings are hypothesis-generating and may relate to the additional mechanical scaffolding and plaque sealing provided by DES in lipidic NA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/2279738","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148263413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Other Side of Medication: A Patient Interview Study on Anti-PCSK9 Monoclonal Antibodies","authors":"Ting Zhang,&nbsp;Doudou Li,&nbsp;Yanmei Ning,&nbsp;Jiana Shi,&nbsp;Ying Hu","doi":"10.1155/cdr/8814045","DOIUrl":"10.1155/cdr/8814045","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors demonstrate significant lipid-lowering effects, but the widespread use of anti-PCSK9 monoclonal antibodies remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>This study is aimed at understanding patients′ real-world experiences with anti-PCSK9 monoclonal antibodies from a subjective perspective and identifying key factors influencing medication adherence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A qualitative research methodology was employed, involving face-to-face semistructured in-depth interviews with 24 individuals who had previously used anti-PCSK9 monoclonal antibodies. The interviews were guided by a thematic framework approach and recorded in their entirety. Posttranscription, Colaizzi′s phenomenological analysis method was utilized to systematically collect and interpret patient-reported subjective experiences.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among those continuing treatment, the most common motivating factors were the anti-PCSK9 monoclonal antibodies′ favorable efficacy and fewer adverse reactions. Among those discontinuing treatment, the primary reasons for stopping were high medication costs (62.5%), insufficient recognition of the necessity for continued use (62.5%), and unwillingness to use injection administration (68.75%). The underlying determinants of patients′ behavioral patterns can be elucidated and mitigated by applying the health belief model and the theory of planned behavior.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Research findings indicate that patients′ willingness to use medication is primarily influenced by three factors: perceived good efficacy, health awareness, and fear of needles and economic burden. We are aimed at enhancing long-term clinical benefits for patients and improving treatment adherence, establishing education about drug efficacy and necessity, promoting innovation of nasal spray or long-acting implant formulations, and achieving precise medical insurance coverage for high-risk populations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ChiCTR registration number: ChiCTR2500101339</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/8814045","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lycorine Attenuates Cardiac Fibrosis Through the Regulation of PYK2 Expression and Activity","authors":"Xiuxiu Gao,&nbsp;Ying Zhang,&nbsp;Dongzhe Li,&nbsp;Yufei Chen,&nbsp;Weimiao Qi,&nbsp;Shufang Cui,&nbsp;Chen Wang,&nbsp;Zhong Wang,&nbsp;Quanyi Wang","doi":"10.1155/cdr/9031925","DOIUrl":"10.1155/cdr/9031925","url":null,"abstract":"<p>Lycorine (LYC), the most abundant monomeric compound from <i>Lycoris radiata</i> bulbs, possesses a range of biological activities, including antipulmonary fibrosis and cardioprotective effects. However, its role in regulating pathological cardiac remodeling, particularly in cardiac fibrosis, remains unclear. In this study, we used transforming growth factor-<i>β</i>1 (TGF-<i>β</i>1) to stimulate NIH/3T3 cells and primary rat cardiac fibroblasts, which were in vitro models of pathological fibroblast activation, and established a mouse model of cardiac fibrosis via intraperitoneal injection of doxorubicin (DOX). The effects of LYC on TGF-<i>β</i>1-induced fibroblast activation and migration were assessed using Western blotting, quantitative PCR, scratch assays, and EdU staining. Cardiac damage and fibrosis were evaluated in vivo by echocardiography, enzyme-linked immunosorbent assay (ELISA), and Masson’s trichrome staining. Through transcriptomic sequencing and bioinformatic analyses, proline-rich tyrosine kinase 2 (PYK2) was identified as a potential target of LYC. This finding was further validated using siPYK2 and the PYK2 inhibitor PF4618433 in TGF-<i>β</i>1-induced NIH/3T3 cells. Our results demonstrated that LYC effectively suppressed fibroblast activation, proliferation, and migration. In addition, LYC significantly ameliorated cardiac dysfunction and reduced collagen deposition in myocardial tissues, thereby attenuating the progression of cardiac fibrosis. Mechanistically, these effects were attributed to the regulation of PYK2 expression and activity by LYC. This study provides a scientific basis for understanding the mechanism of LYC in improving cardiac fibrosis and highlights PYK2 as a potential therapeutic target for the treatment of cardiac fibrosis.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/9031925","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Antithrombotic Management of Nonvalvular Atrial Fibrillation in Patients Undergoing Percutaneous Coronary Intervention in China: A Cross-Sectional Study","authors":"Jiwei Yu,&nbsp;Shuolin Liu,&nbsp;Run Du,&nbsp;Qinglan Tao,&nbsp;Jinzhou Zhu,&nbsp;Fenghua Ding,&nbsp;Ruiyan Zhang,&nbsp;Zhengbin Zhu","doi":"10.1155/cdr/5163410","DOIUrl":"10.1155/cdr/5163410","url":null,"abstract":"<p>Antithrombotic therapy in patients with nonvalvular atrial fibrillation (NVAF) undergoing percutaneous coronary intervention (PCI) is clinically challenging, with real-world strategies often remaining inconsistent. This study analyzed 2020 annual data from the Shanghai Cardiac Intervention Quality Control Center, encompassing 23,115 patients who underwent PCI across 36 centers in Shanghai. Among these, 1306 (5.65%) patients with a confirmed diagnosis of NVAF were enrolled. Dual antiplatelet therapy (DAPT) was the most common antithrombotic regimen (584, 44.7%). Anticoagulation therapy was administered to only 478 (55.8%) of male patients with a CHA₂DS₂-VASc score of ≥ 2 and 207 (55.6%) of female patients with a CHA₂DS₂-VASc score of ≥ 3. Significant differences were observed across antithrombotic strategy groups regarding gender distribution, age, atrial fibrillation (AF) type, coronary artery disease type, and history of congestive heart failure (CHF), hypertension, stroke, or myocardial infarction (MI). Patients receiving oral anticoagulants (OACs) showed higher rates of persistent AF (53.2% vs. 33.9%, <i>p</i> &lt; 0.001) and more frequent histories of CHF and stroke. Conversely, patients not receiving OAC therapy demonstrated a higher proportion of paroxysmal AF (66.1% vs. 46.8%, <i>p</i> &lt; 0.001) and prior MI. A substantial gap persists between guideline recommendations and real-world antithrombotic management in Chinese AF patients undergoing PCI. Key challenges include the underutilization of OAC therapy, a high prevalence of reduced-dose anticoagulation, and a potential overreliance on DAPT. These findings highlight the urgent need to improve adherence to evidence-based guidelines and conduct personalized risk–benefit assessments.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/5163410","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148162033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}